NCT00323076 is a Phase 1, PHASE2 clinical trial of 18F-FAZA PET Imaging in Renal Cell Carcinoma, sponsored by AHS Cancer Control Alberta.

Who is sponsoring NCT00323076?

NCT00323076 is sponsored by AHS Cancer Control Alberta.

What drugs are being tested in NCT00323076?

Interventions in NCT00323076: 18F-FAZA PET Imaging.

What condition does NCT00323076 study?

NCT00323076 studies Renal Cell Carcinoma, Neuroendocrine Tumours.

Is NCT00323076 still recruiting?

NCT00323076 is currently terminated. Last updated 26 August 2019.

Last reviewed 2019-08-26 · How we verify

NCT00323076

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Terminated Phase 1, PHASE2 Last updated 26 August 2019

What this trial tests

Phase 1, PHASE2 trial testing 18F-FAZA PET Imaging in Renal Cell Carcinoma in 92 participants. Terminated before completion.

Timeline

12 September 2006

Primary endpoint
4 February 2019

4 February 2019

Quick facts

Lead sponsor	AHS Cancer Control Alberta
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	92
Start date	12 September 2006
Primary completion	4 February 2019
Estimated completion	4 February 2019
Sites	1 location across Canada

Drugs / interventions tested

18F-FAZA PET Imaging — full drug profile →

Conditions studied

Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
Neuroendocrine Tumours — all drugs for Neuroendocrine Tumours →

Sponsor

AHS Cancer Control Alberta — full company profile →

Who can join

16 and older, any sex, with Renal Cell Carcinoma or Neuroendocrine Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity. The presence of hypoxia (low oxygen) is associated with poor prognosis in a variety of tumour types and treatment strategies targeting hypoxic cells have been developed. The PET tracer \[18\]F-FAZA can identify hypoxic areas, and changes in uptake during treatment may predict tumour response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting

Other AHS Cancer Control Alberta trials

Trials by the same sponsor.

NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00323076 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
Last refreshed: 26 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00323076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing